# ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

> **NCT04891198** · PHASE2 · RECRUITING · sponsor: **3D Medicines (Sichuan) Co., Ltd.** · enrollment: 126 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Envafolimab

## Key facts

- **NCT ID:** NCT04891198
- **Lead sponsor:** 3D Medicines (Sichuan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-06
- **Primary completion:** 2027-08-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891198, "ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04891198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*